Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 30, 2024
Distillery Therapeutics
Butyrate prodrug with increased oral bioavailability for autoimmune diseases
BioCentury | Apr 3, 2024
Data Byte
Last minute flurry brings FDA’s first-quarter NME approvals to 10
Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive
BioCentury | Jun 23, 2023
Regulation
CHMP departs from FDA again in neuro, with Amylyx’ ALS therapy
CHMP’s June opinions: Amylyx therapy denied, plus positive opinions for two new medicines and eight label extensions
BioCentury | May 25, 2023
Deals
May 24 Quick Takes: ElevateBio unveils $401M round, base editing deal with Novo
Plus: Phase III miss for Mirati’s sitravatinib in NSCLC and updates from CMS, Phathom, OnKure, Braeburn, Pyxis-Apexigen, IPI
BioCentury | Nov 2, 2022
Deals
Alkermes mulling cancer spinout, giving neuro business path to profitability
CEO Pops suggests IRA’s dynamics around pricing of cancer biologics ‘reinforced’ decision to explore separation
BioCentury | Aug 18, 2022
Product Development
Rise of the dead Cas to edit the epigenome
Start-ups are tuning gene expression by hitching a range of effector domains to catalytically dead CRISPR machinery
BioCentury | Aug 4, 2021
Deals
Aug. 3 Quick Takes: BeiGene picks N.J. for new campus
Plus Zentera, Iterative Scopes, BMS, Novartis, Mestag, Engrail, AbCellera-Tachyon, Outlook
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Mar 16, 2021
Product Development
The clinical pipeline for Alzheimer’s disease: Data Byte
The early stage Alzheimer’s pipeline moves beyond amyloid
BioCentury | Mar 5, 2021
Deals
March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA
A year to the day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. raised $117 million in a series B round led by Viking Global
Items per page:
1 - 10 of 901